Brokerages Anticipate Miragen Therapeutics Inc (NASDAQ:MGEN) to Announce -$0.30 Earnings Per Share
Wall Street analysts predict that Miragen Therapeutics Inc (NASDAQ:MGEN) will announce earnings of ($0.30) per share for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Miragen Therapeutics’ earnings. The lowest EPS estimate is ($0.39) and the highest is ($0.18). Miragen Therapeutics posted earnings of ($0.29) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 3.4%. The firm is expected to announce its next earnings results on Wednesday, November 6th.
According to Zacks, analysts expect that Miragen Therapeutics will report full-year earnings of ($1.12) per share for the current year, with EPS estimates ranging from ($1.41) to ($0.73). For the next fiscal year, analysts anticipate that the business will post earnings of ($1.06) per share, with EPS estimates ranging from ($1.51) to ($0.58). Zacks’ EPS averages are a mean average based on a survey of research analysts that that provide coverage for Miragen Therapeutics.
Miragen Therapeutics (NASDAQ:MGEN) last announced its quarterly earnings data on Wednesday, August 7th. The medical research company reported ($0.29) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.37) by $0.08. Miragen Therapeutics had a negative net margin of 925.52% and a negative return on equity of 78.14%. The company had revenue of $2.51 million during the quarter, compared to analysts’ expectations of $0.89 million.
Shares of NASDAQ MGEN traded down $0.06 during trading on Tuesday, hitting $1.17. 111,100 shares of the company traded hands, compared to its average volume of 194,560. Miragen Therapeutics has a 1 year low of $0.98 and a 1 year high of $6.43. The stock has a 50-day moving average of $1.99. The company has a market cap of $37.26 million, a price-to-earnings ratio of -1.06 and a beta of 1.12. The company has a debt-to-equity ratio of 0.17, a current ratio of 7.90 and a quick ratio of 7.90.
Institutional investors have recently made changes to their positions in the stock. Bank of America Corp DE boosted its position in Miragen Therapeutics by 35.9% during the 4th quarter. Bank of America Corp DE now owns 33,116 shares of the medical research company’s stock worth $100,000 after purchasing an additional 8,756 shares during the period. D. E. Shaw & Co. Inc. bought a new stake in Miragen Therapeutics during the 4th quarter valued at approximately $179,000. Bank of New York Mellon Corp raised its stake in Miragen Therapeutics by 59.1% during the 4th quarter. Bank of New York Mellon Corp now owns 99,844 shares of the medical research company’s stock valued at $302,000 after purchasing an additional 37,101 shares during the period. Motley Fool Asset Management LLC raised its stake in Miragen Therapeutics by 19.8% during the 1st quarter. Motley Fool Asset Management LLC now owns 173,998 shares of the medical research company’s stock valued at $485,000 after purchasing an additional 28,760 shares during the period. Finally, Deutsche Bank AG raised its stake in Miragen Therapeutics by 266.7% during the 4th quarter. Deutsche Bank AG now owns 190,653 shares of the medical research company’s stock valued at $577,000 after purchasing an additional 138,657 shares during the period. 42.68% of the stock is owned by hedge funds and other institutional investors.
Miragen Therapeutics Company Profile
Miragen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its three lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous, ocular, and idiopathic pulmonary fibrosis; and MRG-110, an inhibitor of miR-92, a microRNA expressed in endothelial cells for the treatment of heart failure, as well as surgical incisions in high risk populations, severe lacerations, and severe burns in the United States and Japan.
Read More: Calculate Your Return on Investment (ROI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Miragen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miragen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.